后发性白内障的生物靶向治疗

后发性白内障是白内障摘出术后或晶状体外伤后,残留的皮质或晶状体上皮细胞( LECs)增生形成的混浊,又称后囊膜混浊,是白内障摘出术后最常见的并发症,亦是白内障患者术后视力下降的主要原因.国内外研究表明,术后LECs的残留和增生是后发性白内障发生、发展的关键因素.关于如何有效地防治后发性白内障一直是眼科学者关注的焦点,包括药物治疗、激光治疗和手术治疗.近年来,其生物靶向治疗成为国内外学者研究的热点,包括一些抗LECs增生药物的局部应用或通过制备转染抗LECs抗体和免疫毒素的载体以抑制LECs的增生或基因治疗等.就近十年来相关研究的进展及发展趋势进行综述.

Biological targeted therapy of after-cataract

After cataract,called posterior capsule opacification (PCO),is resulted from residual cortex or the proliferation of lens epithelial cells following extracapsular cataract extraction,and it is thought to be themost common complication and the main reason of eyesight decline after modern extracapsular cataract surgery.Lens epithelial cells remaining in the capsular bag after surgery play an important role in PCO.How to prevent and treat PCO is the focus of attention of eye scholars,and the major treating methods are administration of drug,laser and surgery.Recent years,scholars in home and abroad are interested in biological targeted therapy to prevent PCO,such as the topical application of antiproliferation of LECs,preparation of vector transfected immunotoxin and gene theropy etc.The research progress in recent years in the biological therapy of PCO were reviewed.